Novacyt SA (Paris:ALNOV) (AIM: NCYT), a specialist in clinical diagnostics, announced on Monday the signing by its molecular testing division, Primerdesign Ltd, of an exclusive supply agreement worth a minimum of USD3m with Genesis Diagnostics.
Genesis Diagnostics is a US-based full service diagnostic laboratory that offers clinical diagnostic testing, oral fluid drug testing and services focused on drug monitoring, substance abuse programmes, infectious disease and personalised medicine.
Under this supply agreement, Primerdesign will develop and supply 384 well plate molecular assay panels for respiratory, women's health, sexually transmitted, wound and urinary tract infections for Genesis Diagnostics to use in its clinical service laboratory based in Langhorne, Pennsylvania.
Also, Primerdesign will be appointed the exclusive product manufacturer of the panel for a minimum of five years.
Reportedly, the supply of products under the agreement is expected to commence in early 2019 and Genesis Diagnostics will purchase minimum quantities of product to the value of USD600,000 per year.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer